Publicaciones en colaboración con investigadores/as de Hospital San Pedro (13)

2022

  1. Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019

    HIV Medicine, Vol. 23, Núm. 7, pp. 705-716

2021

  1. COVID-19 in hospitalized HIV-positive and HIV-negative patients: A matched study

    HIV Medicine, Vol. 22, Núm. 9, pp. 867-876

  2. Redefining therapeutic success in HIV patients: An expert view

    Journal of Antimicrobial Chemotherapy, Vol. 76, Núm. 10, pp. 2501-2518

2020

  1. Risk of cardiovascular disease in patients with HIV infection undergoing antiretroviral therapy

    Revista Clinica Espanola, Vol. 220, Núm. 3, pp. 149-154

2019

  1. Effects of immunonutrition in advanced human immunodeficiency virus disease: A randomized placebo-controlled clinical trial (Promaltia study)

    Clinical Infectious Diseases, Vol. 68, Núm. 1, pp. 120-130

  2. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018)

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 3, pp. 195-202

  3. Predictive factors of renal impairment in HIV-infected patients on antiretroviral therapy: Results from the VACH longitudinal cohort study

    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, Vol. 39, Núm. 5, pp. 497-505

  4. Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 37, Núm. 6, pp. 373-379

2016

  1. Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics

    Open Forum Infectious Diseases, Vol. 3, Núm. 2

  2. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013

    Journal of Infection, Vol. 72, Núm. 5, pp. 587-596

  3. Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy

    HIV Medicine, Vol. 17, Núm. 9, pp. 653-661

2014

  1. A low-cost, sustainable, second generation system for surveillance of people living with HIV in Spain: 10-year trends in behavioural and clinical indicators, 2002 to 2011

    Eurosurveillance, Vol. 19, Núm. 20

2005

  1. Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: Final results of the EFADITE trial

    Antiviral Therapy, Vol. 10, Núm. 7, pp. 825-832